Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › CCCC

SILVERARC CAPITAL MANAGEMENT, LLC position in CCCC

C4 THERAPEUTICS INC · Health Care

SILVERARC CAPITAL MANAGEMENT, LLC reported holding 3,454,647 shares of CCCC (C4 THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$11.5M, representing 1.47% of its reported portfolio and ranking #21 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed CCCC holdings in 10 of the last 11 reported quarters, going back to Q1 2024.

Latest position (Q3 2026)3.45M sh
Reported value held$11.50M
Portfolio Weight1.47%
First reportedQ1 2024
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How SILVERARC CAPITAL MANAGEMENT, LLC's CCCC position evolved

SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in CCCC in Q1 2024 at 150,000 shares (US$1.2M). The position peaked in Q2 2026 at 3,032,060 shares, worth US$14.2M. Across 10 filings, SILVERARC CAPITAL MANAGEMENT, LLC increased the stake 4 time(s), trimmed it 2 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 3,454,647 shares valued at US$11.5M — an increase of 422,587 shares quarter over quarter.. Notable position changes include a 714% increase in Q4 2024 (shares fell 56% over the following quarter), a 28% trim in Q1 2025 (shares fell 11% over the following quarter), a 59% increase in Q2 2026 (shares fell 29% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 150.00K $1.23M New
Q2 2024 150.00K $693.00K Hold
Q3 2024 150.00K $855.00K Hold
Q4 2024 1.22M $4.40M Add
Q1 2025 882.30K $1.41M Reduce
Q3 2025 1.90M $4.21M New
Q4 2025 1.99M $3.81M Add
Q1 2026 1.91M $5.03M Reduce
Q2 2026 3.03M $14.16M Add
Q3 2026 3.45M $11.50M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CCCC and 13F data

CCCC (C4 THERAPEUTICS INC) is a Health Care company. 49 other funds we track also report a position in CCCC — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$37.4M), Lynx1 Capital Management LP (US$34.2M), Bain Capital Life Sciences Investors, LLC (US$33.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CCCC

All CCCC fund holders →

FAQ

How long has SILVERARC CAPITAL MANAGEMENT, LLC held CCCC?

SILVERARC CAPITAL MANAGEMENT, LLC has disclosed CCCC holdings in 10 of the last 11 reported quarters, going back to Q1 2024.

What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in CCCC?

As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 3.45M shares of CCCC (C4 THERAPEUTICS INC), valued at $11.50M, representing 1.47% of its reported portfolio and ranking #21.

Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling CCCC?

In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC increased its position in CCCC. The position peaked in Q2 2026 at 3.03M shares.

Which other funds hold CCCC?

Other major institutional holders of CCCC include RA CAPITAL MANAGEMENT, L.P., Lynx1 Capital Management LP, Bain Capital Life Sciences Investors, LLC, among 49 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.